Mesenchymal Stem Cells Market Report 2026

The mesenchymal stem cells market size has grown rapidly in recent years. It will grow from $3.81 billion in 2025 to $4.29 billion in 2026 at a compound annual growth rate (CAGR) of 12.6%. The growth in the historic period can be attributed to increasing prevalence of chronic diseases, early adoption of stem cell-based therapies, rising stem cell research funding, expansion of cord blood banking, initial advancements in cell isolation technologies.

The mesenchymal stem cells market size is expected to see rapid growth in the next few years. It will grow to $6.54 billion in 2030 at a compound annual growth rate (CAGR) of 11.1%. The growth in the forecast period can be attributed to growing demand for regenerative medicine, rising commercialization of allogeneic therapies, development of advanced cell culture systems, growth in personalized stem cell treatments, increasing investment in clinical trials. Major trends in the forecast period include advancement in regenerative medicine development, AI-supported stem cell characterization, automated bioprocessing and cell expansion, cloud-integrated msc research data platforms, growth in sustainable cell culture technologies.

The increasing awareness of regenerative medicine is expected to drive the growth of the mesenchymal stem cells (MSC) market in the coming years. Regenerative medicine, a rapidly evolving interdisciplinary field, focuses on repairing, replacing, or regenerating cells, tissues, or organs to restore impaired function caused by congenital defects, diseases, trauma, or aging. Its adoption is rising due to factors such as the expansion of clinical trials, the growing prevalence of chronic and age-related conditions, and advancements in personalized medicine. Mesenchymal stem cells (MSCs) are particularly promising in this field because of their ability to differentiate into multiple cell types, modulate immune responses, and promote tissue repair across a wide range of medical conditions. For instance, in August 2023, the Alliance for Regenerative Medicine reported 2,760 cells, gene, and tissue-engineering therapeutic developers worldwide in Q1 2023, up 101% from 1,369 in Q1 2022. Additionally, a July 2023 report by the American Society of Gene & Cell Therapy (ASGCT) and Citeline noted that Phase II gene therapies increased from 247 at the end of Q1 2023 to 260 by the end of Q2, highlighting the rapid growth and adoption of regenerative approaches, which is driving the MSC market forward.

Major companies operating in the mesenchymal stem cells (MSCs) market are embracing advanced technologies, such as GMP-compliant isolation, to enhance their market presence. GMP (Good Manufacturing Practice)-compliant isolation refers to the procedure of isolating cells, including mesenchymal stem cells (MSCs), following GMP guidelines to ensure consistent production and quality control. For example, in July 2023, PromoCell, a Germany-based biotechnology firm, introduced PromoExQ MSC Growth Medium XF, a serum- and xeno-free medium developed for the expansion of human mesenchymal stem cells (MSCs) within a Good Manufacturing Practice (GMP)-regulated framework. This medium is produced under the highest quality standards and holds certification from the EXCiPACT GMP scheme, ensuring reliable growth and maintenance of MSCs derived from sources such as bone marrow, umbilical cord matrix, and adipose tissue.

In May 2024, BioSolution Designs (BSD), a US-based biotechnology invention studio, collaborated with RoosterBio, Inc. The partnership is aimed at streamlining the development and production of engineered human mesenchymal stem/stromal cell (MSC)-derived therapies and exosome-based treatments by combining BSD’s multigenic design platform with RoosterBio’s cell processing and scalable manufacturing expertise. Together, they seek to accelerate the clinical development of next-generation cell therapies. RoosterBio, Inc. is a US-based company specializing in adult human mesenchymal stem/stromal cells (hMSCs).

Major companies operating in the mesenchymal stem cells market are Thermo Fischer Scientific Inc., Danaher Corporation, Merck KgaA, Becton, Dickinson, and Company, Fujifilm Holdings Corporation, Corning Inc., Daiichi Sankyo, Lonza Group, Terumo Corporation, Sartorius AG, Getinge AB, Bio-Rad Laboratories, Eppendorf AG, Bio-Techne Corporation, STEMCELL Technologies Inc., Miltenyi Biotec GmBH, Takara Bio Group, Organogenesis Holdings Inc., Vericel Corporation, HiMedia Laboratories, PromoCell GmbH, CellGenix GmBH, Anterogen Co. Ltd., Pluristem Therapeutics Inc., American Cryostem Corporation.

North America was the largest region in the mesenchymal stem cells market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the mesenchymal stem cells market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the mesenchymal stem cells market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs on medical-grade reagents, cell culture media, and bioprocessing equipment have increased production costs for MSC research and clinical development, especially in regions dependent on imported laboratory supplies such as Asia-Pacific and Latin America. These tariffs impact the supply chain for autologous and allogeneic MSC manufacturing workflows. However, they also encourage domestic production of bioprocessing consumables, stimulate local biotechnology investment, and support long-term cost optimization within the MSC industry.

The mesenchymal stem cells market research report is one of a series of new reports that provides mesenchymal stem cells market statistics, including mesenchymal stem cells industry global market size, regional shares, competitors with a mesenchymal stem cells market share, detailed mesenchymal stem cells market segments, market trends and opportunities, and any further data you may need to thrive in the mesenchymal stem cells industry. This mesenchymal stem cells market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Mesenchymal stem cells (MSCs) are a type of multipotent adult stem cell present in various tissues throughout the body, including bone marrow, adipose tissue, umbilical cord blood, and dental pulp. These cells possess the capacity to differentiate into multiple cell types, such as osteoblasts (bone cells) and chondrocytes (cartilage cells), and are utilized in the treatment of various conditions, including bone and cartilage repair, myocardial infarction, and neurological disorders.

The primary categories of mesenchymal stem cells are autologous and allogeneic. Autologous refers to a medical procedure or treatment in which cells, tissues, or substances are collected from an individual and then reintroduced into the same individual. The different product types include cells and cell lines, kits, media and reagents, and others, along with various workflow types, such as cell sourcing and isolation, culture and cryopreservation, differentiation, and characterization. These are applied for multiple indications, including bone and cartilage repair, cardiovascular diseases, inflammatory and immunological disorders, liver diseases, cancer, GvHD, and others, as well as in various applications, such as disease modeling, drug development and discovery, stem cell banking, tissue engineering, toxicology studies, and more.

The mesenchymal stem cells market consists of revenues earned by entities by providing services such as cell isolation and culture techniques, cryopreservation and storage, custom cell development, and MSC-based therapeutics development. The market value includes the value of related goods sold by the service provider or included within the service offering. The mesenchymal stem cells market also includes sales of MSC differentiation inducers, scaffolds and matrices, MSC-derived exosomes, and cryopreservation agents. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.